Découvrez nos professeurs et professeures!

Jacques Simard

Vice-doyen

Jacques Simard
Centre de recherche sur le cancer
Centre de recherche du CHU de Québec - Université Laval
Partager la fiche :

Contribution à la recherche

Axe de recherche de l'Université Laval :

Santé et bien-être durables

Thématiques de recherche de la Faculté de médecine :

Oncologie
Santé des populations et pratiques optimales en santé
Bioinformatique / données massives (big data)
Transfert des connaissances

Domaines et intérêts de recherche du (de la) professeur(e) :

Cancer
  • Cancer du sein
  • Cancer héréditaire
  • Cancers hormonaux-dépendants
  • Génétique du cancer
Génétique humaine
  • Gènes de susceptibilité
  • Génétique et éthique
  • Génétique moléculaire
  • Génomique
  • Polymorphisme
Santé des populations
Services de santé
Génomique et protéomique

Projets de recherche

  • Fonds institutionnel d'exploitation des infrastructures pour l'Université Laval - Fondation Canadienne pour l'innovation (La) - Fonds d'exploitation des infrastructures (FEI), co-chercheur - 2002-04-01 au 2025-03-31
  • Observatoire international sur les impacts sociétaux de l'intelligence artificielle et du numérique - Fonds de recherche du Québec - Société et culture, Université Laval - Fonds internes - Appel à propositions : création d’un Observatoire international sur les impacts sociétaux de l’intelligence artificielle et du numérique, co-chercheur - 2018-04-01 au 2024-03-31
  • Chaire de recherche du Canada en oncogénétique - Instituts de recherche en santé du Canada - Chaires de recherche du Canada - Fonctionnement, chercheur principal - 2015-03-01 au 2022-06-30
  • From correlation to causation in genomics: identifying mechanisms underlying disease - Instituts de recherche en santé du Canada - Subventions Fondation, University of Toronto, co-chercheur - 2015-07-01 au 2022-06-30
  • Personalized Risk Assesment for Prevention and Early Detection of Breast Cancer : Integration and Implementation (PERSPECTIVE II) - Regroupement de compagnies et corporations canadiennes, Fondation du CHU de Québec, Génome Québec, Ministère de la santé (Ontario), Ministère de l'Économie, de la Science et de l'Innovation, Instituts de recherche en santé du Canada, Fondation du cancer du sein du Québec, Génome Canada - Projets de recherche appliquée à grande échelle - Large-Scale Applied Research Project, chercheur principal - 2017-11-01 au 2022-03-31
  • Fonds Merck - Contribution FMed (50%) salaire chercheurs-boursiers qui retardent demande FRQS J2 d'une année. - Fondation de l'Université Laval, chercheur principal - 2017-04-01 au 2022-03-31
  • Personalized Risk Assesment for Prevention and Early Detection of Breast Cancer : Integration and Implementation (PERSPECTIVE II) : Activité 1.1 - Génome Québec, Instituts de recherche en santé du Canada - Projets de recherche appliquée à grande échelle - Large-Scale Applied Research Project, chercheur principal - 2017-11-01 au 2022-03-31
  • Personalized Risk Assesment for Prevention and Early Detection of Breast Cancer : Integration and Implementation (PERSPECTIVE II) : Activité 1.2 - Instituts de recherche en santé du Canada, Génome Québec - Projets de recherche appliquée à grande échelle - Large-Scale Applied Research Project, chercheur principal - 2017-11-01 au 2022-03-31
  • Personalized Risk Assesment for Prevention and Early Detection of Breast Cancer : Integration and Implementation (PERSPECTIVE II) : Activité 2.3 - Génome Québec - Projets de recherche appliquée à grande échelle - Large-Scale Applied Research Project, chercheur principal - 2017-11-01 au 2022-03-31
  • Personalized Risk Assesment for Prevention and Early Detection of Breast Cancer : Integration and Implementation (PERSPECTIVE II) : Activités 3.1/3.2 - Génome Québec - Projets de recherche appliquée à grande échelle - Large-Scale Applied Research Project, chercheur principal - 2017-11-01 au 2022-03-31
  • Personalized Risk Assesment for Prevention and Early Detection of Breast Cancer : Integration and Implementation (PERSPECTIVE II) : Activité 3.3 - Génome Québec - Projets de recherche appliquée à grande échelle - Large-Scale Applied Research Project, chercheur principal - 2017-11-01 au 2022-03-31
  • Personalized Risk Assesment for Prevention and Early Detection of Breast Cancer : Integration and Implementation (PERSPECTIVE II) : Activité 5 - Génome Québec - Projets de recherche appliquée à grande échelle - Large-Scale Applied Research Project, chercheur principal - 2017-11-01 au 2022-03-31
  • Personalized Risk Assesment for Prevention and Early Detection of Breast Cancer : Integration and Implementation (PERSPECTIVE II) : R92 - Transferts de fonds interinstitutions - Génome Québec, Instituts de recherche en santé du Canada - Projets de recherche appliquée à grande échelle - Large-Scale Applied Research Project, chercheur principal - 2017-11-01 au 2022-03-31
  • Quand innovations technologique et organisationnelle vont de pair: Un modèle collaboratif pour rendre l'oncogénétique plus agile, accessible et efficiente - Fonds de recherche du Québec - Santé, co-chercheur - 2020-04-01 au 2022-03-31

Publications

  • A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers, , Nat Commun, 2021, 10.1038/s41467-020-20496-3
  • A Collaborative Model to Implement Flexible, Accessible and Efficient Oncogenetic Services for Hereditary Breast and Ovarian Cancer: The C-MOnGene Study, , Cancers (Basel), 2021, 10.3390/cancers13112729
  • Author Correction: A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers, , Nat Commun, 2021, 10.1038/s41467-021-23162-4
  • Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores, , J Natl Cancer Inst, 2021, 10.1093/jnci/djab147
  • Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women, , N Engl J Med, 2021, 10.1056/NEJMoa1913948
  • CYP3A7*1C allele: linking premenopausal oestrone and progesterone levels with risk of hormone receptor-positive breast cancers, , Br J Cancer, 2021, 10.1038/s41416-020-01185-w
  • Evaluation of the association of heterozygous germline variants in NTHL1 with breast cancer predisposition: an international multi-center study of 47,180 subjects, , NPJ Breast Cancer, 2021, 10.1038/s41523-021-00255-3
  • Functional annotation of the 2q35 breast cancer risk locus implicates a structural variant in influencing activity of a long-range enhancer element, , Am J Hum Genet, 2021, 10.1016/j.ajhg.2021.05.013
  • Large-scale cross-cancer fine-mapping of the 5p15.33 region reveals multiple independent signals, , HGG Adv, 2021, 10.1016/j.xhgg.2021.100041
  • Mendelian randomisation study of smoking exposure in relation to breast cancer risk, , Br J Cancer, 2021, 10.1038/s41416-021-01432-8
  • Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers: an international cohort study, , Am J Obstet Gynecol, 2021, 10.1016/j.ajog.2021.01.014
  • PALB2 Variants: Protein Domains and Cancer Susceptibility, , Trends Cancer, 2021, 10.1016/j.trecan.2020.10.002
  • Personalized Risk Assessment for Prevention and Early Detection of Breast Cancer: Integration and Implementation (PERSPECTIVE I&I), , J Pers Med, 2021, 10.3390/jpm11060511
  • Personalizing Breast Cancer Screening Based on Polygenic Risk and Family History, , J Natl Cancer Inst, 2021, 10.1093/jnci/djaa127
  • Pleiotropy-guided transcriptome imputation from normal and tumor tissues identifies candidate susceptibility genes for breast and ovarian cancer, , HGG Adv, 2021, 10.1016/j.xhgg.2021.100042
  • Potential of polygenic risk scores for improving population estimates of women's breast cancer genetic risks, , Genet Med, 2021, 10.1038/s41436-021-01258-y
  • Prospective evaluation of a breast-cancer risk model integrating classical risk factors and polygenic risk in 15 cohorts from six countries, , Int J Epidemiol, 2021, 10.1093/ije/dyab036
  • Risk-Stratified Approach to Breast Cancer Screening in Canada: Women's Knowledge of the Legislative Context and Concerns about Discrimination from Genetic and Other Predictive Health Data, , J Pers Med, 2021, 10.3390/jpm11080726
  • Should Age-Dependent Absolute Risk Thresholds Be Used for Risk Stratification in Risk-Stratified Breast Cancer Screening?, , J Pers Med, 2021, 10.3390/jpm11090916
  • The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant, , Genet Med, 2021, 10.1038/s41436-021-01198-7
  • Toward a Population-Based Breast Cancer Risk Stratification Approach? The Needs and Concerns of Healthcare Providers, , J Pers Med, 2021, 10.3390/jpm11060540
  • Women's Views on Multifactorial Breast Cancer Risk Assessment and Risk-Stratified Screening: A Population-Based Survey from Four Provinces in Canada, , J Pers Med, 2021, 10.3390/jpm11020095
  • A Mendelian randomization analysis of circulating lipid traits and breast cancer risk, , Int J Epidemiol, 2020, 10.1093/ije/dyz242
  • A network analysis to identify mediators of germline-driven differences in breast cancer prognosis, , Nat Commun, 2020, 10.1038/s41467-019-14100-6
  • Alcohol Consumption, Cigarette Smoking, and Risk of Breast Cancer for BRCA1 and BRCA2 Mutation Carriers: Results from The BRCA1 and BRCA2 Cohort Consortium, , Cancer Epidemiol Biomarkers Prev, 2020, 10.1158/1055-9965.Epi-19-0546
  • Assessment of polygenic architecture and risk prediction based on common variants across fourteen cancers, , Nat Commun, 2020, 10.1038/s41467-020-16483-3
  • Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness, , Cancer Res, 2020, 10.1158/0008-5472.Can-19-1840
  • Association of germline variation with the survival of women with BRCA1/2 pathogenic variants and breast cancer, , NPJ Breast Cancer, 2020, 10.1038/s41523-020-00185-6
  • Characterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants: Results From the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA), , JAMA Oncol, 2020, 10.1001/jamaoncol.2020.2134
  • Correction to: Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers, , Breast Cancer Res, 2020, 10.1186/s13058-020-01259-w
  • European polygenic risk score for prediction of breast cancer shows similar performance in Asian women, , Nat Commun, 2020, 10.1038/s41467-020-17680-w
  • Evaluation of associations between genetically predicted circulating protein biomarkers and breast cancer risk, , Int J Cancer, 2020, 10.1002/ijc.32542
  • Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes, , Nat Genet, 2020, 10.1038/s41588-019-0537-1
  • Functional characterization of 84 PALB2 variants of uncertain significance, , Genet Med, 2020, 10.1038/s41436-019-0682-z
  • Genetically Predicted Levels of DNA Methylation Biomarkers and Breast Cancer Risk: Data From 228 951 Women of European Descent, , J Natl Cancer Inst, 2020, 10.1093/jnci/djz109
  • Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses, , Nat Genet, 2020, 10.1038/s41588-020-0609-2
  • Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk, , Sci Rep, 2020, 10.1038/s41598-020-65665-y
  • Identification of novel breast cancer susceptibility loci in meta-analyses conducted among Asian and European descendants, , Nat Commun, 2020, 10.1038/s41467-020-15046-w
  • Personalized early detection and prevention of breast cancer: ENVISION consensus statement, , Nat Rev Clin Oncol, 2020, 10.1038/s41571-020-0388-9
  • Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants, , Genet Med, 2020, 10.1038/s41436-020-0862-x
  • Publisher Correction: Personalized early detection and prevention of breast cancer: ENVISION consensus statement, , Nat Rev Clin Oncol, 2020, 10.1038/s41571-020-0412-0
  • Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers, , Breast Cancer Res, 2020, 10.1186/s13058-020-1247-4
  • Sequence kernel association test for survival outcomes in the presence of a non-susceptible fraction, , Biostatistics, 2020, 10.1093/biostatistics/kxy075
  • Survey of primary care physicians' views about breast and ovarian cancer screening for true BRCA1/2 non-carriers, , J Community Genet, 2020, 10.1007/s12687-019-00438-3
  • Transcriptome-wide association study of breast cancer risk by estrogen-receptor status, , Genet Epidemiol, 2020, 10.1002/gepi.22288
  • A global functional analysis of missense mutations reveals two major hotspots in the PALB2 tumor suppressor, , Nucleic Acids Res, 2019, 10.1093/nar/gkz780
  • A response to "Personalised medicine and population health: breast and ovarian cancer", , Hum Genet, 2019, 10.1007/s00439-019-01984-z
  • Associations of obesity and circulating insulin and glucose with breast cancer risk: a Mendelian randomization analysis, , Int J Epidemiol, 2019, 10.1093/ije/dyy201
  • Authors' response: Associations of obesity and circulating insulin and glucose with breast cancer risk, , Int J Epidemiol, 2019, 10.1093/ije/dyz015
  • BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors, , Genet Med, 2019, 10.1038/s41436-018-0406-9
  • Body mass index and the association between low-density lipoprotein cholesterol as predicted by HMGCR genetic variants and breast cancer risk, , Int J Epidemiol, 2019, 10.1093/ije/dyz047
  • Correction: BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors, , Genet Med, 2019, 10.1038/s41436-019-0459-4
  • DSNetwork: An Integrative Approach to Visualize Predictions of Variants' Deleteriousness, , Front Genet, 2019, 10.3389/fgene.2019.01349
  • Envisioning Implementation of a Personalized Approach in Breast Cancer Screening Programs: Stakeholder Perspectives, , Healthc Policy, 2019, 10.12927/hcpol.2019.26072
  • Functional analysis of genetic variants in the high-risk breast cancer susceptibility gene PALB2, , Nat Commun, 2019, 10.1038/s41467-019-13194-2
  • Functional Analysis of Promoter Variants in Genes Involved in Sex Steroid Action, DNA Repair and Cell Cycle Control, , Genes (Basel), 2019, 10.3390/genes10030186
  • Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer, , Nat Commun, 2019, 10.1038/s41467-018-08053-5
  • Genome-wide association study of germline variants and breast cancer-specific mortality, , Br J Cancer, 2019, 10.1038/s41416-019-0393-x
  • Health professionals' perspectives on breast cancer risk stratification: understanding evaluation of risk versus screening for disease, , Public Health Rev, 2019, 10.1186/s40985-019-0111-5
  • Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study, , J Natl Cancer Inst, 2019, 10.1093/jnci/djy132
  • Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers, , Br J Cancer, 2019, 10.1038/s41416-019-0492-8
  • Open science precision medicine in Canada: Points to consider, , Facets (Ott), 2019
  • Organizational challenges to equity in the delivery of services within a new personalized risk-based approach to breast cancer screening, , New Genet Soc, 2019
  • Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes, , Am J Hum Genet, 2019, 10.1016/j.ajhg.2018.11.002
  • Prevalence of BRCA1 and BRCA2 pathogenic variants in a large, unselected breast cancer cohort, , Int J Cancer, 2019, 10.1002/ijc.31841
  • Publisher Correction: Shared heritability and functional enrichment across six solid cancers, , Nat Commun, 2019, 10.1038/s41467-019-12095-8
  • Re-evaluating genetic variants identified in candidate gene studies of breast cancer risk using data from nearly 280,000 women of Asian and European ancestry, , EBioMedicine, 2019, 10.1016/j.ebiom.2019.09.006
  • Shared heritability and functional enrichment across six solid cancers, , Nat Commun, 2019, 10.1038/s41467-018-08054-4
  • The association between weight at birth and breast cancer risk revisited using Mendelian randomisation, , Eur J Epidemiol, 2019, 10.1007/s10654-019-00485-7
  • The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer, , NPJ Breast Cancer, 2019, 10.1038/s41523-019-0127-5
  • The Passing of Dr. Fernand Labrie (1937-2019): The legacy of excellence in science, , J Steroid Biochem Mol Biol, 2019, 10.1016/j.jsbmb.2019.02.005
  • The Tumor Suppressor PALB2: Inside Out, , Trends Biochem Sci, 2019, 10.1016/j.tibs.2018.10.008
  • Two truncating variants in FANCC and breast cancer risk, , Sci Rep, 2019, 10.1038/s41598-019-48804-y
  • A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation, , EMBO Mol Med, 2018, 10.15252/emmm.201809172
  • A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk, , Cancer Res, 2018, 10.1158/0008-5472.Can-18-0951
  • A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer, , Nat Genet, 2018, 10.1038/s41588-018-0132-x
  • Differential Burden of Rare and Common Variants on Tumor Characteristics, Survival, and Mode of Detection in Breast Cancer, , Cancer Res, 2018, 10.1158/0008-5472.Can-18-1018
  • Disentangling the determinants of interest and willingness-to-pay for breast cancer susceptibility testing in the general population: a cross-sectional Web-based survey among women of Québec (Canada), , BMJ Open, 2018, 10.1136/bmjopen-2017-016662
  • Inherited mutations in BRCA1 and BRCA2 in an unselected multiethnic cohort of Asian patients with breast cancer and healthy controls from Malaysia, , J Med Genet, 2018, 10.1136/jmedgenet-2017-104947
  • Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations, , Hum Mutat, 2018, 10.1002/humu.23406
  • On the readiness of physicians for pharmacogenomics testing: an empirical assessment, , Pharmacogenomics J, 2018, 10.1038/tpj.2017.22
  • Oral Contraceptive Use and Breast Cancer Risk: Retrospective and Prospective Analyses From a BRCA1 and BRCA2 Mutation Carrier Cohort Study, , JNCI Cancer Spectr, 2018, 10.1093/jncics/pky023
  • Publisher Correction: Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation, , Nat Commun, 2018, 10.1038/ncomms16193
  • The Influence of Number and Timing of Pregnancies on Breast Cancer Risk for Women With BRCA1 or BRCA2 Mutations, , JNCI Cancer Spectr, 2018, 10.1093/jncics/pky078
  • Association analysis identifies 65 new breast cancer risk loci, , Nature, 2017, 10.1038/nature24284
  • Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3, , Breast Cancer Res Treat, 2017, 10.1007/s10549-016-4018-2
  • Breast Cancer Risk Estimation and Personal Insurance: A Qualitative Study Presenting Perspectives from Canadian Patients and Decision Makers, , Front Genet, 2017, 10.3389/fgene.2017.00128
  • Do women change their breast cancer mammogram screening behaviour after BRCA1/2 testing?, , Fam Cancer, 2017, 10.1007/s10689-016-9920-6
  • Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers, , J Natl Cancer Inst, 2017, 10.1093/jnci/djw302
  • Gene-environment interactions involving functional variants: Results from the Breast Cancer Association Consortium, , Int J Cancer, 2017, 10.1002/ijc.30859
  • Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer, , Nat Genet, 2017, 10.1038/ng.3826
  • Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer, , Nat Genet, 2017, 10.1038/ng.3785
  • Increased Use of BRCA Mutation Test in Unaffected Women Over the Period 2004-2014 in the U.S.: Further Evidence of the "Angelina Jolie Effect"?, , Am J Prev Med, 2017, 10.1016/j.amepre.2017.05.016
  • Inherited Chromosomally Integrated Human Herpesvirus 6 and Breast Cancer, , Cancer Epidemiol Biomarkers Prev, 2017, 10.1158/1055-9965.Epi-16-0735
  • No evidence of excessive cancer screening in female noncarriers from BRCA1/2 mutation-positive families, , Curr Oncol, 2017, 10.3747/co.24.3759
  • PHIP - a novel candidate breast cancer susceptibility locus on 6q14.1, , Oncotarget, 2017, 10.18632/oncotarget.21800
  • Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores, , J Clin Oncol, 2017, 10.1200/jco.2016.69.4935
  • Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers, , Jama, 2017, 10.1001/jama.2017.7112
  • The OncoArray Consortium: A Network for Understanding the Genetic Architecture of Common Cancers, , Cancer Epidemiol Biomarkers Prev, 2017, 10.1158/1055-9965.Epi-16-0106
  • Transcriptional signature of lymphoblastoid cell lines of BRCA1, BRCA2 and non-BRCA1/2 high risk breast cancer families, , Oncotarget, 2017, 10.18632/oncotarget.20219
  • VEXOR: an integrative environment for prioritization of functional variants in fine-mapping analysis, , Bioinformatics, 2017, 10.1093/bioinformatics/btw826
  • ABRAXAS (FAM175A) and Breast Cancer Susceptibility: No Evidence of Association in the Breast Cancer Family Registry, , PLoS One, 2016, 10.1371/journal.pone.0156820
  • An intergenic risk locus containing an enhancer deletion in 2q35 modulates breast cancer risk by deregulating IGFBP5 expression, , Hum Mol Genet, 2016, 10.1093/hmg/ddw223
  • Association of breast cancer risk with genetic variants showing differential allelic expression: Identification of a novel breast cancer susceptibility locus at 4q21, , Oncotarget, 2016, 10.18632/oncotarget.12818
  • Association of genetic susceptibility variants for type 2 diabetes with breast cancer risk in women of European ancestry, , Cancer Causes Control, 2016, 10.1007/s10552-016-0741-6
  • BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers, , J Natl Cancer Inst, 2016, 10.1093/jnci/djv315
  • Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170, , Nat Genet, 2016, 10.1038/ng.3521
  • Clinical follow-up and breast and ovarian cancer screening of true BRCA1/2 noncarriers: a qualitative investigation, , Genet Med, 2016, 10.1038/gim.2015.135
  • Evidence that the 5p12 Variant rs10941679 Confers Susceptibility to Estrogen-Receptor-Positive Breast Cancer through FGF10 and MRPS30 Regulation, , Am J Hum Genet, 2016, 10.1016/j.ajhg.2016.07.017
  • Fine scale mapping of the 17q22 breast cancer locus using dense SNPs, genotyped within the Collaborative Oncological Gene-Environment Study (COGs), , Sci Rep, 2016, 10.1038/srep32512
  • Fine-Mapping of the 1p11.2 Breast Cancer Susceptibility Locus, , PLoS One, 2016, 10.1371/journal.pone.0160316
  • Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers, , PLoS One, 2016, 10.1371/journal.pone.0158801
  • Fine-scale mapping of 8q24 locus identifies multiple independent risk variants for breast cancer, , Int J Cancer, 2016, 10.1002/ijc.30150
  • Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus, , Nat Commun, 2016, 10.1038/ncomms12675
  • Genetic predisposition to ductal carcinoma in situ of the breast, , Breast Cancer Res, 2016, 10.1186/s13058-016-0675-7
  • Genetic variation in the immunosuppression pathway genes and breast cancer susceptibility: a pooled analysis of 42,510 cases and 40,577 controls from the Breast Cancer Association Consortium, , Hum Genet, 2016, 10.1007/s00439-015-1616-8
  • Genetically Predicted Body Mass Index and Breast Cancer Risk: Mendelian Randomization Analyses of Data from 145,000 Women of European Descent, , PLoS Med, 2016, 10.1371/journal.pmed.1002105
  • Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types, , Cancer Discov, 2016, 10.1158/2159-8290.Cd-15-1227
  • Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer, , Nat Commun, 2016, 10.1038/ncomms11375
  • Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus, , Breast Cancer Res, 2016, 10.1186/s13058-016-0718-0
  • Incorporating truncating variants in PALB2, CHEK2, and ATM into the BOADICEA breast cancer risk model, , Genet Med, 2016, 10.1038/gim.2016.31
  • Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women, , Breast Cancer Res, 2016, 10.1186/s13058-016-0768-3
  • No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer, , Gynecol Oncol, 2016, 10.1016/j.ygyno.2015.04.034
  • PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS, , J Med Genet, 2016, 10.1136/jmedgenet-2016-103839
  • Prediction of breast cancer risk based on common genetic variants in women of East Asian ancestry, , Breast Cancer Res, 2016, 10.1186/s13058-016-0786-1
  • RAD51B in Familial Breast Cancer, , PLoS One, 2016, 10.1371/journal.pone.0153788
  • Recommendations on breast cancer screening and prevention in the context of implementing risk stratification: impending changes to current policies, , Curr Oncol, 2016, 10.3747/co.23.2961
  • rs2735383, located at a microRNA binding site in the 3'UTR of NBS1, is not associated with breast cancer risk, , Sci Rep, 2016, 10.1038/srep36874
  • The knowledge value-chain of genetic counseling for breast cancer: an empirical assessment of prediction and communication processes, , Fam Cancer, 2016, 10.1007/s10689-015-9835-7
  • Usefulness of Canadian Public Health Insurance Administrative Databases to Assess Breast and Ovarian Cancer Screening Imaging Technologies for BRCA1/2 Mutation Carriers, , Can Assoc Radiol J, 2016
  • Usefulness of Canadian Public Health Insurance Administrative Databases to Assess Breast and Ovarian Cancer Screening Imaging Technologies for BRCA1/2 Mutation Carriers, , Can Assoc Radiol J, 2016, 10.1016/j.carj.2015.12.003
  • An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers, , Breast Cancer Res, 2015, 10.1186/s13058-015-0567-2
  • Analysis of multivariate failure times in the presence of selection bias with application to breast cancer, , J R Stat Soc Ser C Appl Stat, 2015
  • Assessing associations between the AURKA-HMMR-TPX2-TUBG1 functional module and breast cancer risk in BRCA1/2 mutation carriers, , PLoS One, 2015, 10.1371/journal.pone.0120020
  • Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer, , Jama, 2015, 10.1001/jama.2014.5985
  • Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers, , Cancer Epidemiol Biomarkers Prev, 2015, 10.1158/1055-9965.Epi-14-0532
  • Ethical challenges and innovations in the dissemination of genomic data: the experience of the PERSPECTIVE project, , Adv Genomics Genet, 2015
  • Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2, , Hum Mol Genet, 2015, 10.1093/hmg/ddv035
  • Fine-scale mapping of the 4q24 locus identifies two independent loci associated with breast cancer risk, , Cancer Epidemiol Biomarkers Prev, 2015, 10.1158/1055-9965.Epi-15-0363
  • Fine-scale mapping of the 5q11.2 breast cancer locus reveals at least three independent risk variants regulating MAP3K1, , Am J Hum Genet, 2015, 10.1016/j.ajhg.2014.11.009
  • Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer, , Nat Genet, 2015, 10.1038/ng.3242
  • Height and Breast Cancer Risk: Evidence From Prospective Studies and Mendelian Randomization, , J Natl Cancer Inst, 2015, 10.1093/jnci/djv219
  • Identification and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer risk, , Hum Mol Genet, 2015, 10.1093/hmg/ddu431
  • Identification of six new susceptibility loci for invasive epithelial ovarian cancer, , Nat Genet, 2015, 10.1038/ng.3185
  • Inherited variants in the inner centromere protein (INCENP) gene of the chromosomal passenger complex contribute to the susceptibility of ER-negative breast cancer, , Carcinogenesis, 2015, 10.1093/carcin/bgu326
  • Large-scale genomic analyses link reproductive aging to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repair, , Nat Genet, 2015, 10.1038/ng.3412
  • Multiple novel prostate cancer susceptibility signals identified by fine-mapping of known risk loci among Europeans, , Hum Mol Genet, 2015, 10.1093/hmg/ddv203
  • Novel Associations between Common Breast Cancer Susceptibility Variants and Risk-Predicting Mammographic Density Measures, , Cancer Res, 2015, 10.1158/0008-5472.Can-14-2012
  • Polymorphisms in a Putative Enhancer at the 10q21.2 Breast Cancer Risk Locus Regulate NRBF2 Expression, , Am J Hum Genet, 2015, 10.1016/j.ajhg.2015.05.002
  • Prediction of breast cancer risk based on profiling with common genetic variants, , J Natl Cancer Inst, 2015, 10.1093/jnci/djv036
  • SNP Set Association Testing for Survival Outcomes in the Presence of Intrafamilial Correlation, , Genet Epidemiol, 2015, 10.1002/gepi.21914
  • SNP-SNP interaction analysis of NF-κB signaling pathway on breast cancer survival, , Oncotarget, 2015, 10.18632/oncotarget.4991
  • A large-scale assessment of two-way SNP interactions in breast cancer susceptibility using 46,450 cases and 42,461 controls from the breast cancer association consortium, , Hum Mol Genet, 2014, 10.1093/hmg/ddt581
  • Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers, , Breast Cancer Res, 2014, 10.1186/s13058-014-0492-9
  • Common non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association Consortium, , Hum Mol Genet, 2014, 10.1093/hmg/ddu311
  • DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers, , PLoS Genet, 2014, 10.1371/journal.pgen.1004256
  • Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation, , Nat Commun, 2014, 10.1038/ncomms5999
  • FGF receptor genes and breast cancer susceptibility: results from the Breast Cancer Association Consortium, , Br J Cancer, 2014, 10.1038/bjc.2013.769
  • Genetic predisposition to in situ and invasive lobular carcinoma of the breast, , PLoS Genet, 2014, 10.1371/journal.pgen.1004285
  • Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study, , Breast Cancer Res, 2014, 10.1186/bcr3662
  • Genetic variation in mitotic regulatory pathway genes is associated with breast tumor grade, , Hum Mol Genet, 2014, 10.1093/hmg/ddu300
  • Identification of new genetic susceptibility loci for breast cancer through consideration of gene-environment interactions, , Genet Epidemiol, 2014, 10.1002/gepi.21771
  • Life insurance: genomic stratification and risk classification, , Eur J Hum Genet, 2014, 10.1038/ejhg.2013.228
  • Medical genetic counseling for breast cancer in primary care: a synthesis of major determinants of physicians' practices in primary care settings, , Public Health Genomics, 2014, 10.1159/000362358
  • MicroRNA related polymorphisms and breast cancer risk, , PLoS One, 2014, 10.1371/journal.pone.0109973
  • A focus group study on breast cancer risk presentation: one format does not fit all, , Eur J Hum Genet, 2013, 10.1038/ejhg.2012.248
  • Analysis of ZNF350/ZBRK1 promoter variants and breast cancer susceptibility in non-BRCA1/2 French Canadian breast cancer families, , J Hum Genet, 2013, 10.1038/jhg.2012.127
  • COMPLEXO: identifying the missing heritability of breast cancer via next generation collaboration, , Breast Cancer Res, 2013, 10.1186/bcr3434
  • Exploring resources for intrafamilial communication of cancer genetic risk: we still need to talk, , Eur J Hum Genet, 2013, 10.1038/ejhg.2012.286
  • Family communication following BRCA1/2 genetic testing: a close look at the process, , J Genet Couns, 2013, 10.1007/s10897-012-9559-x
  • Fine-scale mapping of the FGFR2 breast cancer risk locus: putative functional variants differentially bind FOXA1 and E2F1, , Am J Hum Genet, 2013, 10.1016/j.ajhg.2013.10.026
  • Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers, , Am J Hum Genet, 2013, 10.1016/j.ajhg.2013.01.002
  • Genetic discrimination and life insurance: a systematic review of the evidence, , BMC Med, 2013, 10.1186/1741-7015-11-25
  • Genome-wide association studies identify four ER negative-specific breast cancer risk loci, , Nat Genet, 2013, 10.1038/ng.2561
  • Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk, , PLoS Genet, 2013, 10.1371/journal.pgen.1003212
  • Identification of a BRCA2-specific modifier locus at 6p24 related to breast cancer risk, , PLoS Genet, 2013, 10.1371/journal.pgen.1003173
  • Large-scale genotyping identifies 41 new loci associated with breast cancer risk, , Nat Genet, 2013, 10.1038/ng.2563
  • Lessons learned and challenges posed in cancer genetics. Introduction, , J Intern Med, 2013, 10.1111/joim.12129
  • Life events may contribute to family communication about cancer risk following BRCA1/2 testing, , J Genet Couns, 2013, 10.1007/s10897-012-9531-9
  • Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer, , Nat Genet, 2013, 10.1038/ng.2566
  • Personalized medicine and access to health care: potential for inequitable access?, , Eur J Hum Genet, 2013, 10.1038/ejhg.2012.149
  • Polymorphic variations in the FANCA gene in high-risk non-BRCA1/2 breast cancer individuals from the French Canadian population, , Mol Oncol, 2013, 10.1016/j.molonc.2012.08.002
  • Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers, , J Clin Oncol, 2013, 10.1200/jco.2012.47.8313
  • A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers, , Cancer Epidemiol Biomarkers Prev, 2012, 10.1158/1055-9965.Epi-12-0229
  • Analysis of Xq27-28 linkage in the international consortium for prostate cancer genetics (ICPCG) families, , BMC Med Genet, 2012, 10.1186/1471-2350-13-46
  • Association of PHB 1630 C>T and MTHFR 677 C>T polymorphisms with breast and ovarian cancer risk in BRCA1/2 mutation carriers: results from a multicenter study, , Br J Cancer, 2012, 10.1038/bjc.2012.160
  • Chromosomes 4 and 8 implicated in a genome wide SNP linkage scan of 762 prostate cancer families collected by the ICPCG, , Prostate, 2012, 10.1002/pros.21443
  • Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers, , Breast Cancer Res, 2012, 10.1186/bcr3121
  • Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers, , Cancer Epidemiol Biomarkers Prev, 2012, 10.1158/1055-9965.Epi-11-0888
  • Effectiveness of risk-reducing salpingo-oophorectomy in preventing ovarian cancer in a high-risk French Canadian population, , Int J Gynecol Cancer, 2012, 10.1097/IGC.0b013e318257b936
  • ENIGMA--evidence-based network for the interpretation of germline mutant alleles: an international initiative to evaluate risk and clinical significance associated with sequence variation in BRCA1 and BRCA2 genes, , Hum Mutat, 2012, 10.1002/humu.21628
  • Evaluation of chromosome 6p22 as a breast cancer risk modifier locus in a follow-up study of BRCA2 mutation carriers, , Breast Cancer Res Treat, 2012, 10.1007/s10549-012-2255-6
  • Functional analysis of promoter variants in KU70 and their role in cancer susceptibility, , Genes Chromosomes Cancer, 2012, 10.1002/gcc.21983
  • Incidence and predictors of positive and negative effects of BRCA1/2 genetic testing on familial relationships: a 3-year follow-up study, , Genet Med, 2012, 10.1038/gim.0b013e3182310a7f
  • Influence of the family cluster effect on psychosocial variables in families undergoing BRCA1/2 genetic testing for cancer susceptibility, , Psychooncology, 2012, 10.1002/pon.1936
  • Legal liability and the uncertain nature of risk prediction: the case of breast cancer risk prediction models, , Public Health Genomics, 2012, 10.1159/000342138
  • Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers, , Hum Mutat, 2012, 10.1002/humu.22025
  • Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA), , Cancer Epidemiol Biomarkers Prev, 2012, 10.1158/1055-9965.Epi-11-0775
  • Self-reported mammography use following BRCA1/2 genetic testing may be overestimated, , Fam Cancer, 2012, 10.1007/s10689-011-9490-6
  • Breast and ovarian cancer screening of non-carriers from BRCA1/2 mutation-positive families: 2-year follow-up of cohorts from France and Quebec, , Eur J Hum Genet, 2011, 10.1038/ejhg.2010.227
  • Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers, , Hum Mol Genet, 2011, 10.1093/hmg/ddr226
  • Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2, , Breast Cancer Res, 2011, 10.1186/bcr3052
  • Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriers, , Hum Mol Genet, 2011, 10.1093/hmg/ddr388
  • Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers, , J Natl Cancer Inst, 2011, 10.1093/jnci/djq494
  • Return of research results: general principles and international perspectives, , J Law Med Ethics, 2011, 10.1111/j.1748-720X.2011.00625.x
  • Systematic mixed-methods reviews are not ready to be assessed with the available tools, , J Clin Epidemiol, 2011, 10.1016/j.jclinepi.2011.01.002
  • The CYP17A1 -34T > C polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers, , Breast Cancer Res Treat, 2011, 10.1007/s10549-010-1123-5
  • A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population, , Nat Genet, 2010, 10.1038/ng.669
  • Association of the variants CASP8 D302H and CASP10 V410I with breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers, , Cancer Epidemiol Biomarkers Prev, 2010, 10.1158/1055-9965.Epi-10-0517
  • Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction, , Cancer Res, 2010, 10.1158/0008-5472.Can-10-1907
  • Evaluation of the contribution of the three breast cancer susceptibility genes CHEK2, STK11, and PALB2 in non-BRCA1/2 French Canadian families with high risk of breast cancer, , Genet Test Mol Biomarkers, 2010, 10.1089/gtmb.2010.0027
  • Genetic testing, physicians and the law: will the tortoise ever catch up with the hare?, , Ann Health Law, 2010
  • Pooled analysis indicates that the GSTT1 deletion, GSTM1 deletion, and GSTP1 Ile105Val polymorphisms do not modify breast cancer risk in BRCA1 and BRCA2 mutation carriers, , Breast Cancer Res Treat, 2010, 10.1007/s10549-009-0601-0
  • Analysis of 17beta-hydroxysteroid dehydrogenase types 5, 7, and 12 genetic sequence variants in breast cancer cases from French Canadian Families with high risk of breast and ovarian cancer, , J Steroid Biochem Mol Biol, 2009, 10.1016/j.jsbmb.2009.05.005
  • Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers, , Hum Mol Genet, 2009, 10.1093/hmg/ddp372
  • Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA), , Br J Cancer, 2009, 10.1038/sj.bjc.6605416
  • Genetic sequence variations of BRCA1-interacting genes AURKA, BAP1, BARD1 and DHX9 in French Canadian families with high risk of breast cancer, , J Hum Genet, 2009, 10.1038/jhg.2009.6
  • No association of TGFB1 L10P genotypes and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a multi-center cohort study, , Breast Cancer Res Treat, 2009, 10.1007/s10549-008-0064-8
  • Reproductive and hormonal factors, and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: results from the International BRCA1/2 Carrier Cohort Study, , Cancer Epidemiol Biomarkers Prev, 2009, 10.1158/1055-9965.Epi-08-0546
  • The TP53 Arg72Pro and MDM2 309G>T polymorphisms are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers, , Br J Cancer, 2009, 10.1038/sj.bjc.6605279
  • Variations in the NBN/NBS1 gene and the risk of breast cancer in non-BRCA1/2 French Canadian families with high risk of breast cancer, , BMC Cancer, 2009, 10.1186/1471-2407-9-181
  • Analysis of GADD45A sequence variations in French Canadian families with high risk of breast cancer, , J Hum Genet, 2008, 10.1007/s10038-008-0276-0
  • Characterization of HSD17B1 sequence variants in breast cancer cases from French Canadian families with high risk of breast and ovarian cancer, , J Steroid Biochem Mol Biol, 2008, 10.1016/j.jsbmb.2007.10.004
  • Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers, , Am J Hum Genet, 2008, 10.1016/j.ajhg.2008.02.008
  • Genetic variants and haplotype analyses of the ZBRK1/ZNF350 gene in high-risk non BRCA1/2 French Canadian breast and ovarian cancer families, , Int J Cancer, 2008, 10.1002/ijc.23058
  • Health behaviors and psychological distress in women initiating BRCA1/2 genetic testing: comparison with control population, , J Genet Couns, 2008, 10.1007/s10897-008-9150-7
  • Mutation analysis and characterization of HSD17B2 sequence variants in breast cancer cases from French Canadian families with high risk of breast and ovarian cancer, , J Mol Endocrinol, 2008, 10.1677/jme-07-0101
  • Mutational analysis of the breast cancer susceptibility gene BRIP1 /BACH1/FANCJ in high-risk non-BRCA1/BRCA2 breast cancer families, , J Hum Genet, 2008, 10.1007/s10038-008-0285-z
  • Age at menarche and menopause and breast cancer risk in the International BRCA1/2 Carrier Cohort Study, , Cancer Epidemiol Biomarkers Prev, 2007, 10.1158/1055-9965.Epi-06-0829
  • An international initiative to identify genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: the Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA), , Breast Cancer Res, 2007, 10.1186/bcr1670
  • AURKA F31I polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a consortium of investigators of modifiers of BRCA1/2 study, , Cancer Epidemiol Biomarkers Prev, 2007, 10.1158/1055-9965.Epi-07-0129
  • Clinical management recommendations for surveillance and risk-reduction strategies for hereditary breast and ovarian cancer among individuals carrying a deleterious BRCA1 or BRCA2 mutation, , J Obstet Gynaecol Can, 2007, 10.1016/s1701-2163(16)32349-0
  • Effect of the Women's Health Initiative study publication on hormone replacement therapy use among women who have undergone BRCA1/2 testing, , Cancer Epidemiol Biomarkers Prev, 2007, 10.1158/1055-9965.Epi-06-0340
  • Evaluation of BRCA1 and BRCA2 mutation prevalence, risk prediction models and a multistep testing approach in French-Canadian families with high risk of breast and ovarian cancer, , J Med Genet, 2007, 10.1136/jmg.2006.044388
  • Factors associated with an individual's decision to withdraw from genetic testing for breast and ovarian cancer susceptibility: implications for counseling, , Genet Test, 2007, 10.1089/gte.2006.9998
  • Genetic sequence variations and ADPRT haplotype analysis in French Canadian families with high risk of breast cancer, , J Hum Genet, 2007, 10.1007/s10038-007-0203-9
  • Germline mutations in the breast cancer susceptibility gene PTEN are rare in high-risk non-BRCA1/2 French Canadian breast cancer families, , Fam Cancer, 2007, 10.1007/s10689-007-9151-y
  • Oral contraceptives and breast cancer risk in the international BRCA1/2 carrier cohort study: a report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group, , J Clin Oncol, 2007, 10.1200/jco.2007.11.1179
  • RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies, , Am J Hum Genet, 2007, 10.1086/522611
  • Variations in Rates: why we need clinical management recommendations, , Open Med, 2007
  • Androgens, DHEA and breast cancer, , Androgens and reproductive aging, 2006
  • BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families, , Breast Cancer Res, 2006, 10.1186/bcr1365
  • Effect of chest X-rays on the risk of breast cancer among BRCA1/2 mutation carriers in the international BRCA1/2 carrier cohort study: a report from the EMBRACE, GENEPSO, GEO-HEBON, and IBCCS Collaborators' Group, , J Clin Oncol, 2006, 10.1200/jco.2005.03.3126
  • Guidelines for disclosing genetic information to family members: from development to use, , Fam Cancer, 2006, 10.1007/s10689-005-2581-5
  • Mutation analysis and characterization of ATR sequence variants in breast cancer cases from high-risk French Canadian breast/ovarian cancer families, , BMC Cancer, 2006, 10.1186/1471-2407-6-230
  • No Evidence of BRCA1/2 genomic rearrangements in high-risk French-Canadian breast/ovarian cancer families, , Genet Test, 2006, 10.1089/gte.2006.10.104
  • Partnering in oncogenetic research--the INHERIT BRCAs experience: opportunities and challenges, , Fam Cancer, 2006, 10.1007/s10689-005-2570-8
  • Pooled genome linkage scan of aggressive prostate cancer: results from the International Consortium for Prostate Cancer Genetics, , Hum Genet, 2006, 10.1007/s00439-006-0219-9
  • Pregnancies, breast-feeding, and breast cancer risk in the International BRCA1/2 Carrier Cohort Study (IBCCS), , J Natl Cancer Inst, 2006, 10.1093/jnci/djj132
  • The AIB1 polyglutamine repeat does not modify breast cancer risk in BRCA1 and BRCA2 mutation carriers, , Cancer Epidemiol Biomarkers Prev, 2006, 10.1158/1055-9965.Epi-05-0709
  • The emergence of an ethical duty to disclose genetic research results: international perspectives, , Eur J Hum Genet, 2006, 10.1038/sj.ejhg.5201690
  • Use of dietary supplements among women at high risk of hereditary breast and ovarian cancer (HBOC) tested for cancer susceptibility, , Nutr Cancer, 2006, 10.1207/s15327914nc5402_1
  • Using the impact of event scale to evaluate distress in the context of genetic testing for breast cancer susceptibility, , Psychol Rep, 2006, 10.2466/pr0.98.3.873-881
  • 17alpha-hydroxylase/17,20-Lyase deficiency due to novel compound heterozygote mutations: treatment for tall stature in a female with male pseudohermaphroditism and spontaneous puberty in her affected sister, , J Pediatr Endocrinol Metab, 2005, 10.1515/jpem.2005.18.4.403
  • A combined genomewide linkage scan of 1,233 families for prostate cancer-susceptibility genes conducted by the international consortium for prostate cancer genetics, , Am J Hum Genet, 2005, 10.1086/432377
  • A new alternative splice variant of BRCA1 containing an additional in-frame exon, , Biochim Biophys Acta, 2005, 10.1016/j.bbaexp.2005.08.011
  • Characterization of the guinea pig 3beta-hydroxysteroid dehydrogenase/Delta5-Delta4-isomerase expressed in the adrenal gland and gonads, , J Steroid Biochem Mol Biol, 2005, 10.1016/j.jsbmb.2005.05.011
  • Common BRCA2 variants and modification of breast and ovarian cancer risk in BRCA1 mutation carriers, , Cancer Epidemiol Biomarkers Prev, 2005
  • CYP17 and breast cancer: no overall effect, but what about interactions?, , Breast Cancer Res, 2005, 10.1186/bcr1320
  • Description of the International Consortium For Prostate Cancer Genetics, and failure to replicate linkage of hereditary prostate cancer to 20q13, , Prostate, 2005, 10.1002/pros.20198
  • GATA factors and the nuclear receptors, steroidogenic factor 1/liver receptor homolog 1, are key mutual partners in the regulation of the human 3beta-hydroxysteroid dehydrogenase type 2 promoter, , Mol Endocrinol, 2005, 10.1210/me.2004-0257
  • Gonadotropin-releasing hormone agonists in the treatment of prostate cancer, , Endocr Rev, 2005, 10.1210/er.2004-0017
  • HRT use among women tested for BRCA1/2 mutations following publication of the women's health initiative study results, , J Obstet Gynaecol Can, 2005, 10.1016/s1701-2163(16)30455-8
  • Is dehydroepiandrosterone a hormone?, , J Endocrinol, 2005, 10.1677/joe.1.06264
  • Les enjeux éthiques du partage des résultats de recherche: l'expérience d'INHERIT BRCAS, , La recherche en génétique et en génomique : droits et responsabilités, 2005
  • Macrophage scavenger receptor 1 999C>T (R293X) mutation and risk of prostate cancer, , Cancer Epidemiol Biomarkers Prev, 2005, 10.1158/1055-9965.Epi-04-0202
  • Molecular and genealogical characterization of the R1443X BRCA1 mutation in high-risk French-Canadian breast/ovarian cancer families, , Hum Genet, 2005, 10.1007/s00439-005-1297-9
  • Molecular biology of the 3beta-hydroxysteroid dehydrogenase/delta5-delta4 isomerase gene family, , Endocr Rev, 2005, 10.1210/er.2002-0050
  • No evidence of false reassurance among women with an inconclusive BRCA1/2 genetic test result, , Cancer Epidemiol Biomarkers Prev, 2005, 10.1158/1055-9965.Epi-05-0512
  • Synthesis and structure-activity relationships of analogs of EM-652 (acolbifene), a pure selective estrogen receptor modulator. Study of nitrogen substitution, , J Enzyme Inhib Med Chem, 2005, 10.1080/14756360500043448
  • Are ATM mutations 7271T-->G and IVS10-6T-->G really high-risk breast cancer-susceptibility alleles?, , Cancer Res, 2004, 10.1158/0008-5472.can-03-2678
  • Changes in health-related behaviours following BRCA 1/2 genetic testing: the case of hormone replacement therapy, , J Obstet Gynaecol Can, 2004, 10.1016/s1701-2163(16)30432-7
  • Physicians, genetics and life insurance, , Cmaj, 2004, 10.1503/cmaj.1040127
  • Prostate cancer suceptibility genes, , Prostate Cancer: Understanding the Pathophysiology and Re-Designing A Therapeutic Approach, 2004
  • Structure of primate and rodent orthologs of the prostate cancer susceptibility gene ELAC2, , Biochim Biophys Acta, 2004, 10.1016/j.bbaexp.2004.07.001
  • [From the gene to the clinic: prostate cancer death can now be an exception?], , Med Sci (Paris), 2003, 10.1051/medsci/20031910910
  • BRCA1 wild-type allele modifies risk of ovarian cancer in carriers of BRCA1 germ-line mutations, , Cancer Epidemiol Biomarkers Prev, 2003
  • Characterization and modulation of sex steroid metabolizing activity in normal human keratinocytes in primary culture and HaCaT cells, , J Steroid Biochem Mol Biol, 2003, 10.1016/j.jsbmb.2003.08.006
  • Characterization of a novel mutation causing hepatic lipase deficiency among French Canadians, , J Lipid Res, 2003, 10.1194/jlr.M200479-JLR200
  • Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone, , Endocr Rev, 2003, 10.1210/er.2001-0031
  • Les enjeux éthiques de l'identification d'une susceptibilité génétique au cancer du sein dans un contexte de recherche clinique intégrée, , Les pratiques de recherche biomédicale visitées par la bioéthique, 2003
  • Males With 17[beta]-Hydroxysteroid Dehydrogenase Deficiency, , Endocrinologist, 2003
  • Prostate cancer susceptibility genes: lessons learned and challenges posed, , Endocr Relat Cancer, 2003, 10.1677/erc.0.0100225
  • Results of a genome-wide linkage analysis in prostate cancer families ascertained through the ACTANE consortium, , Prostate, 2003, 10.1002/pros.10301
  • 17b-hydroxysteroid dehydrogenase and 5a-reductase eficiencies, , Genetics of steroid biosynthesis and function, 2002
  • 3b-hydroxysteroid dehydrogenase D5- D4-isomerase deficiency, , Genetics of steroid biosynthesis and function, 2002
  • Congenital adrenal hyperplasia due to 3beta-hydroxysteroid dehydrogenase/Delta(5)-Delta(4) isomerase deficiency, , Semin Reprod Med, 2002, 10.1055/s-2002-35373
  • DHEA replacement therapy as a source of androgens and estrogens at menopause, , Advances in gynecological endocrinology: the proceedings of the plenary sessions of the 8th World Congress of Gynecological Endocrinology, Florence, Italy, December 2000, 2002
  • Genomic organization and expression of the mouse Brca2 gene, , Mamm Genome, 2002, 10.1007/s00335-002-2300-6
  • Glucocorticoids enhance activation of the human type II 3beta-hydroxysteroid dehydrogenase/Delta5-Delta4 isomerase gene, , J Steroid Biochem Mol Biol, 2002, 10.1016/s0960-0760(02)00147-4
  • Perspective: prostate cancer susceptibility genes, , Endocrinology, 2002, 10.1210/endo.143.6.8890
  • Synergistic action of prolactin (PRL) and androgen on PRL-inducible protein gene expression in human breast cancer cells: a unique model for functional cooperation between signal transducer and activator of transcription-5 and androgen receptor, , Mol Endocrinol, 2002, 10.1210/mend.16.7.0875
  • The challenge of connecting genomic knowledge to disease prevention: a Canadian integrative experience, , Community genetics: Past and future, 2002
  • Third and fourth generation SERMs, , Selective estrogen receptor modulators: research and clinical applications, 2002
  • A candidate prostate cancer susceptibility gene at chromosome 17p, , Nat Genet, 2001, 10.1038/84808
  • Crucial role of cytokines in sex steroid formation in normal and tumoral tissues, , Mol Cell Endocrinol, 2001, 10.1016/s0303-7207(00)00387-7
  • DHEA and its transformation into androgens and estrogens in peripheral target tissues: intracrinology, , Front Neuroendocrinol, 2001, 10.1006/frne.2001.0216
  • EM-652 (SCH 57068), a pure SERM in the mammary gland and endometrium, , Ref Gynecol Obstet, 2001
  • EM-652 (SCH57068), a pure SERM having complete antiestrogenic activity in the mammary gland and endometrium, , J Steroid Biochem Mol Biol, 2001, 10.1016/s0960-0760(01)00139-x
  • Evidence of a founder effect for the protein C gene 3363 inserted C mutation in thrombophilic pedigrees of French origin, , Thromb Haemost, 2001
  • Multiple signal transduction pathways mediate interleukin-4-induced 3beta-hydroxysteroid dehydrogenase/Delta5-Delta4 isomerase in normal and tumoral target tissues, , J Steroid Biochem Mol Biol, 2001, 10.1016/s0960-0760(00)00148-5
  • Pure selective estrogen receptor modulators, new molecules having absolute cell specificity ranging from pure antiestrogenic to complete estrogen-like activities, , Adv Protein Chem, 2001, 10.1016/s0065-3233(01)56009-x
  • Support groups for people carrying a BRCA mutation, , Cmaj, 2001
  • A new insight into the molecular basis of 3beta-hydroxysteroid dehydrogenase deficiency, , Endocr Res, 2000, 10.3109/07435800009048597
  • A novel A10E homozygous mutation in the HSD3B2 gene causing severe salt-wasting 3beta-hydroxysteroid dehydrogenase deficiency in 46,XX and 46,XY French-Canadians: evaluation of gonadal function after puberty, , J Clin Endocrinol Metab, 2000, 10.1210/jcem.85.5.6581
  • Combined analysis of hereditary prostate cancer linkage to 1q24-25: results from 772 hereditary prostate cancer families from the International Consortium for Prostate Cancer Genetics, , Am J Hum Genet, 2000, 10.1086/302807
  • DHEA, the precursor of androgens and estrogens in peripheral tissues in the human: intracrinology, , Dehydroepiandrosterone (DHEA): biochemical, physiological and clinical aspects, 2000
  • EM-652 (SCH 57068), a third generation SERM (selective estrogen receptor modulator), acting as pure antiestrogen in the mammary gland and endometrium, , Current knowledge in reproductive medicine: proceedings of the 10th World Congress on Human Reproduction, Salvador, Brazil, 4-8th May, 1999, 2000
  • High risk genes predisposing to prostate cancer development-do they exist?, , Prostate Cancer Prostatic Dis, 2000, 10.1038/sj.pcan.4500478
  • Intracrinology: role of the family of 17 beta-hydroxysteroid dehydrogenases in human physiology and disease, , J Mol Endocrinol, 2000, 10.1677/jme.0.0250001
  • Mechanisms of action of estrogens and antiestrogens, , The menopause at the millennium: proceedings of the 9th World Congress on the Menopause, 2000
  • Multiple signaling pathways mediate interleukin-4-induced 3beta-hydroxysteroid dehydrogenase/delta5-delta4 isomerase type 1 gene expression in human breast cancer cells, , Mol Endocrinol, 2000, 10.1210/mend.14.2.0416
  • Role of 17 beta-hydroxysteroid dehydrogenases in sex steroid formation in peripheral intracrine tissues, , Trends Endocrinol Metab, 2000, 10.1016/s1043-2760(00)00342-8
  • Suggestive evidence for a site specific prostate cancer gene on chromosome 1p36. The CRC/BPG UK Familial Prostate Cancer Study Coordinators and Collaborators. The EU Biomed Collaborators, , J Med Genet, 2000, 10.1136/jmg.37.12.947
  • The exon 13 duplication in the BRCA1 gene is a founder mutation present in geographically diverse populations. The BRCA1 Exon 13 Duplication Screening Group, , Am J Hum Genet, 2000
  • 17beta-hydroxysteroid dehydrogenase (HSD)/17-ketosteroid reductase (KSR) family; nomenclature and main characteristics of the 17HSD/KSR enzymes, , J Mol Endocrinol, 1999, 10.1677/jme.0.0230001
  • EM-652 (SCH 57068), a third generation SERM acting as pure antiestrogen in the mammary gland and endometrium, , J Steroid Biochem Mol Biol, 1999, 10.1016/s0960-0760(99)00065-5
  • Fine mapping of low-density lipoprotein receptor gene by genetic linkage on chromosome 19p13.1-p13.3 and study of the founder effect of four French Canadian low-density lipoprotein receptor gene mutations, , Atherosclerosis, 1999, 10.1016/s0021-9150(98)00267-6
  • Hérédité et cancer du sein : les gènes de susceptibilité BRCA1 et BRCA2, , Actualité Médicale, 1999
  • Impact de l'intracrinologie dans la thérapeutique et le prévention des cancers du sein et de la prostate, et de la ménopause, , Rev Fr Endocrinol Clin, 1999
  • Induction of 3beta-hydroxysteroid dehydrogenase/delta5-delta4 isomerase type 1 gene transcription in human breast cancer cell lines and in normal mammary epithelial cells by interleukin-4 and interleukin-13, , Mol Endocrinol, 1999, 10.1210/mend.13.1.0221
  • Induction of 3beta-hydroxysteroid dehydrogenase/isomerase type 1 expression by interleukin-4 in human normal prostate epithelial cells, immortalized keratinocytes, colon, and cervix cancer cell lines, , Endocrinology, 1999, 10.1210/endo.140.10.7038
  • New insight into the molecular basis of 3beta-hydroxysteroid dehydrogenase deficiency: identification of eight mutations in the HSD3B2 gene eleven patients from seven new families and comparison of the functional properties of twenty-five mutant enzymes, , J Clin Endocrinol Metab, 1999, 10.1210/jcem.84.12.6288
  • p300/CBP is required for transcriptional induction by interleukin-4 and interacts with Stat6, , Nucleic Acids Res, 1999, 10.1093/nar/27.13.2722
  • Parallel solid-phase synthesis of a model library of 7alpha-alkylamide estradiol derivatives as potential estrogen receptor antagonists, , Bioorg Med Chem Lett, 1999, 10.1016/s0960-894x(99)00487-4
  • Proceedings of the Xth International Congress on Hormonal Steroids. Quebec City, Canada 17-21 June 1998, , 1999
  • Relative potency of bicalutamide (Casodex) and flutamide (Eulexin) (Letter to the Editor : reply to Kolvenbag GJ et al; 50:913-919, 1997), , Urology, 1999
  • Role of DHEA transformation into androgens and estrogens in peripheral intracrine tissues, , DHEA: a comprehensive review, 1999
  • Association of specific LDL receptor gene mutations with differential plasma lipoprotein response to simvastatin in young French Canadians with heterozygous familial hypercholesterolemia, , Arterioscler Thromb Vasc Biol, 1998, 10.1161/01.atv.18.6.1007
  • BRCA1 gene expression in reproductive and endocrine tissues in adult cynomolgus monkey, , Ann N Y Acad Sci, 1998, 10.1111/j.1749-6632.1998.tb10828.x
  • DHEA and the intracrine formation of androgens and estrogens in peripheral target tissues: its role during aging, , Steroids, 1998, 10.1016/s0039-128x(98)00007-5
  • Genetic linkage mapping of the CYP11A1 gene encoding the cholesterol side-chain cleavage P450scc close to the CYP1A1 gene and D15S204 in the chromosome 15q22.33-q23 region, , Pharmacogenetics, 1998, 10.1097/00008571-199802000-00007
  • Identification of three mutations in the low-density lipoprotein receptor gene causing familial hypercholesterolemia among French Canadians, , Hum Mutat, 1998, 10.1002/humu.1380110173
  • Linkage analysis of chromosome 1q markers in 136 prostate cancer families. The Cancer Research Campaign/British Prostate Group U.K. Familial Prostate Cancer Study Collaborators, , Am J Hum Genet, 1998, 10.1086/301745
  • Regulation of sex steroid formation by interleukin-4 and interleukin-6 in breast cancer cells, , J Steroid Biochem Mol Biol, 1998, 10.1016/s0960-0760(98)00031-4
  • Type I protein C deficiency in French Canadians: evidence of a founder effect and association of specific protein C gene mutations with plasma protein C levels, , Thromb Haemost, 1998
  • (S)-(+)-4-[7-(2,2-dimethyl-1-oxopropoxy)-4-methyl-2-[4-[2-(1-piperidinyl)-ethoxy]phenyl]-2H-1-benzopyran-3-yl]-phenyl 2,2-dimethylpropanoate (EM-800): a highly potent, specific, and orally active nonsteroidal antiestrogen, , J Med Chem, 1997, 10.1021/jm970095o
  • Blockade of the stimulatory effect of estrogens, OH-tamoxifen, OH-toremifene, droloxifene, and raloxifene on alkaline phosphatase activity by the antiestrogen EM-800 in human endometrial adenocarcinoma Ishikawa cells, , Cancer Res, 1997
  • Characterization of the effects of the novel non-steroidal antiestrogen EM-800 on basal and estrogen-induced proliferation of T-47D, ZR-75-1 and MCF-7 human breast cancer cells in vitro, , Int J Cancer, 1997, 10.1002/(sici)1097-0215(19970926)73:1<104::aid-ijc16>3.0.co;2-g
  • Comparison of in vitro effects of the pure antiandrogens OH-flutamide, Casodex, and nilutamide on androgen-sensitive parameters, , Urology, 1997, 10.1016/s0090-4295(97)00029-0
  • Estimated potency of Casodex: a problematic design, , Urology, 1997
  • Intracrinology and hormone-dependent cancers, , Epitheorese klinikes farmakologias kai farmakokinetikes = Review of clinical pharmacology and pharmacokinetics, 1997
  • Localization of BRCA1 gene expression in adult cynomolgus monkey tissues, , J Histochem Cytochem, 1997, 10.1177/002215549704500901
  • Molecular cloning, upstream sequence and promoter studies of the human gene for the regulatory subunit RII alpha of cAMP-dependent protein kinase, , Biochim Biophys Acta, 1997, 10.1016/s0167-4781(96)00152-2
  • Recent advances in androgen receptor research : relative potencies of pure antiandrogens and implications for prostate cancer therapy, , New diagnostic and treatment modalities in prostate cancer : a comprehensive guide to current strategies in management, 1997
  • Reply by the authors to : Editorial Comment of : Comparison of in vitro effects of the pure antiandrogens OH-flutamide, casodex, and nilutamide on androgen-sensitive parameters, , Urology, 1997
  • Response of symbiotic endomycorrhizal fungi to estrogens and antiestrogens, , Mol Plant Microbe Interact, 1997
  • Structure-function relationships of 3 beta-hydroxysteroid dehydrogenase: contribution made by the molecular genetics of 3 beta-hydroxysteroid dehydrogenase deficiency, , Steroids, 1997, 10.1016/s0039-128x(96)00178-x
  • The key role of 17 beta-hydroxysteroid dehydrogenases in sex steroid biology, , Steroids, 1997, 10.1016/s0039-128x(96)00174-2
  • Androgen receptor antagonists (Chapter 28), , Reproductive endocrinology, surgery, and technology, 1996
  • BRCA2 germline mutations in male breast cancer cases and breast cancer families, , Nat Genet, 1996, 10.1038/ng0596-123
  • Cancer : What are the role and sources of steroid hormones and the possible role of adipose tissue?, , Progress in obesity research, 1996
  • Comparison of BRCA1 polymorphisms, rare sequence variants and/or missense mutations in unaffected and breast/ovarian cancer populations, , Hum Mol Genet, 1996, 10.1093/hmg/5.6.835
  • DHEA and sex steroids : intracrinology in target tissues (Reprinted from Journal of endocrinology, vol. 150, supplement, September 1996), , 1996
  • Generation of an integrated transcription map of the BRCA2 region on chromosome 13q12-q13, , Genomics, 1996, 10.1006/geno.1996.0428
  • Genetic linkage mapping of the human steroid 5 alpha-reductase type 2 gene (SRD5A2) close to D2S352 on chromosome region 2p23-->p22, , Cytogenet Cell Genet, 1996, 10.1159/000134362
  • History of LHRH agonist and combination therapy in prostate cancer, , Endocr Relat Cancer, 1996
  • Interleukin-4 and interleukin-13 inhibit estrogen-induced breast cancer cell proliferation and stimulate GCDFP-15 expression in human breast cancer cells, , Mol Cell Endocrinol, 1996, 10.1016/0303-7207(96)03843-9
  • Localization and regulation of expression of the FAR-17A gene in the hamster flank organs, , J Invest Dermatol, 1996, 10.1111/1523-1747.ep12297867
  • Molecular biology and genetics of the 3 beta-hydroxysteroid dehydrogenase/delta5-delta4 isomerase gene family, , J Endocrinol, 1996
  • Mutation analysis of the BRCA1 gene in 23 families with cases of cancer of the breast, ovary, and multiple other sites, , J Med Genet, 1996, 10.1136/jmg.33.10.814
  • Mutation R96W in cytochrome P450c17 gene causes combined 17 alpha-hydroxylase/17-20-lyase deficiency in two French Canadian patients, , J Clin Endocrinol Metab, 1996, 10.1210/jcem.81.1.8550762
  • Mutations and polymorphisms in the familial early-onset breast cancer (BRCA1) gene. Breast Cancer Information Core, , Hum Mutat, 1996, 10.1002/humu.1380080102
  • Relatives potencies of flutamide and casodex : preclinical studies, , Endocr Relat Cancer, 1996
  • Sources d'androgènes chez l'homme et traitement hormonal du cancer de la prostate (Chapter 16), , Endocrinologie Masculine, 1996
  • The 3b-hydroxysteroid dehydrogenase/isomerase gene family: lessons from type II 3ß-HSD congenital deficiency, , Signal transduction in testicular cells: basic and clinical aspects, 1996
  • The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds, , Nat Genet, 1996, 10.1038/ng0396-333
  • ["Intracrinology". Autonomy and freedom of peripheral tissues], , Ann Endocrinol (Paris), 1995
  • A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene. Implications for presymptomatic testing and screening, , Jama, 1995
  • BRCA1 mutations in Ashkenazi Jewish women, , Am J Hum Genet, 1995
  • DHEA and peripheral androgen and estrogen formation: intracinology, , Ann N Y Acad Sci, 1995, 10.1111/j.1749-6632.1995.tb17369.x
  • Generation of a transcription map at the HSD17B locus centromeric to BRCA1 at 17q21, , Genomics, 1995, 10.1006/geno.1995.1185
  • Genetic linkage mapping of HSD3B1 and HSD3B2 encoding human types I and II 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4-isomerase close to D1S514 and the centromeric D1Z5 locus, , Cytogenet Cell Genet, 1995, 10.1159/000133938
  • Genetic linkage mapping of the dehydroepiandrosterone sulfotransferase (STD) gene on the chromosome 19q13.3 region, , Genomics, 1995, 10.1006/geno.1995.9935
  • Identification and characterization of the G15D mutation found in a male patient with 3 beta-hydroxysteroid dehydrogenase (3 beta-HSD) deficiency: alteration of the putative NAD-binding domain of type II 3 beta-HSD, , Biochemistry, 1995, 10.1021/bi00009a020
  • Interleukin-6 inhibits the potent stimulatory action of androgens, glucocorticoids and interleukin-1 alpha on apolipoprotein D and GCDFP-15 expression in human breast cancer cells, , Int J Cancer, 1995, 10.1002/ijc.2910620614
  • Linkage analysis of 26 Canadian breast and breast-ovarian cancer families, , Hum Genet, 1995, 10.1007/bf00223867
  • Local and systemic reduction by topical finasteride or flutamide of hamster flank organ size and enzyme activity, , J Invest Dermatol, 1995, 10.1111/1523-1747.ep12324390
  • Mapping of the HSD17B2 gene encoding type II 17 beta-hydroxysteroid dehydrogenase close to D16S422 on chromosome 16q24.1-q24.2, , Genomics, 1995, 10.1016/0888-7543(95)80017-g
  • Molecular basis of human 3 beta-hydroxysteroid dehydrogenase deficiency, , J Steroid Biochem Mol Biol, 1995, 10.1016/0960-0760(95)00043-y
  • Nonsalt-losing male pseudohermaphroditism due to the novel homozygous N100S mutation in the type II 3 beta-hydroxysteroid dehydrogenase gene, , J Clin Endocrinol Metab, 1995, 10.1210/jcem.80.7.7608265
  • Occurrence of cytochrome P450c17 mRNA and dehydroepiandrosterone biosynthesis in the rat gastrointestinal tract, , Mol Cell Endocrinol, 1995, 10.1016/0303-7207(95)03553-j
  • Rapid restriction fragment analysis for screening four point mutations of the low-density lipoprotein receptor gene in French Canadians, , Hum Mutat, 1995, 10.1002/humu.1380060307
  • Structure-function relationships and molecular genetics of the 3 beta-hydroxysteroid dehydrogenase gene family, , J Steroid Biochem Mol Biol, 1995, 10.1016/0960-0760(95)00198-0
  • The human type II 17 beta-hydroxysteroid dehydrogenase gene encodes two alternatively spliced mRNA species, , DNA Cell Biol, 1995, 10.1089/dna.1995.14.849
  • Binding of a member of the NF1 family of transcription factors to two distinct cis-acting elements in the promoter and 5'-flanking region of the human cellular retinol binding protein 1 gene, , Mol Endocrinol, 1994, 10.1210/mend.8.6.7935489
  • Common origins of BRCA1 mutations in Canadian breast and ovarian cancer families, , Nat Genet, 1994, 10.1038/ng1294-392
  • Congenital adrenal hyperplasia caused by a novel homozygous frameshift mutation 273 delta AA in type II 3 beta-hydroxysteroid dehydrogenase gene (HSD3B2) in three male patients of Afghan/Pakistani origin, , Hum Mol Genet, 1994, 10.1093/hmg/3.2.327
  • Detection and functional characterization of the novel missense mutation Y254D in type II 3 beta-hydroxysteroid dehydrogenase (3 beta HSD) gene of a female patient with nonsalt-losing 3 beta HSD deficiency, , J Clin Endocrinol Metab, 1994, 10.1210/jcem.78.3.8126127
  • Detection of a novel mutation (stop 468) in exon 10 of the low-density lipoprotein receptor gene causing familial hypercholesterolemia among French Canadians, , Hum Mol Genet, 1994, 10.1093/hmg/3.9.1689
  • Dinucleotide repeat polymorphisms in the HSD3B2 gene, , Hum Mol Genet, 1994, 10.1093/hmg/3.2.384
  • Formation and degradation of dihydrotestosterone by recombinant members of the rat 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase family, , Mol Cell Endocrinol, 1994, 10.1016/0303-7207(94)90066-3
  • Functional characterization of the novel L108W and P186L mutations detected in the type II 3 beta-hydroxysteroid dehydrogenase gene of a male pseudohermaphrodite with congenital adrenal hyperplasia, , Hum Mol Genet, 1994, 10.1093/hmg/3.9.1639
  • Inverse relationships between cell proliferation and basal or androgen-stimulated apolipoprotein D secretion in LNCaP human prostate cancer cells, , J Steroid Biochem Mol Biol, 1994, 10.1016/0960-0760(94)90090-6
  • Le déficit en 3beta-hydroxystéroide déshydrogénase delta5-delta4 isomérase : hétérogénéité des formes cliniques et apport de la biologie, , Rev Fr Endocrinol Clin, 1994
  • Localization of 3 beta-hydroxysteroid dehydrogenase in rat brain as studied by in situ hybridization, , Mol Cell Neurosci, 1994, 10.1006/mcne.1994.1014
  • Molecular basis of congenital adrenal hyperplasia in two siblings with classical nonsalt-losing 3 beta-hydroxysteroid dehydrogenase deficiency, , J Clin Endocrinol Metab, 1994, 10.1210/jcem.79.4.7962268
  • Molecular biology of the intracrine steroidogenic enzymes in the human prostate, , Sex hormones and antihormones in endocrine dependent pathology: basic and clinical aspects: proceedings of an international symposium, Milano, 10-14 April 1994, 1994
  • Molecular genetics, structure-function relationships and tissue-specific expression and tissue-specific expression and regulation of the 3b-hydroxysteroid dehydrogenase/D5-D4 isomerase gene family, , Function of somatic cells in the testis, 1994
  • Multihormonal regulation of dehydroepiandrosterone sulfotransferase messenger ribonucleic acid levels in adult rat liver, , Endocrinology, 1994, 10.1210/endo.134.4.8137732
  • No evidence of mutations in the genes for type I and type II 3 beta-hydroxysteroid dehydrogenase (3 beta HSD) in nonclassical 3 beta HSD deficiency, , J Clin Endocrinol Metab, 1994, 10.1210/jcem.79.6.7989489
  • Opposite effects of prolactin and corticosterone on the expression and activity of 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase in rat skin, , J Invest Dermatol, 1994, 10.1111/1523-1747.ep12389663
  • Potent stimulatory effect of interleukin-1 alpha on apolipoprotein D and gross cystic disease fluid protein-15 expression in human breast-cancer cells, , Int J Cancer, 1994, 10.1002/ijc.2910590319
  • Rapid modulation of ovarian 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase gene expression by prolactin and human chorionic gonadotropin in the hypophysectomized rat, , Mol Cell Endocrinol, 1994, 10.1016/0303-7207(94)90147-3
  • Structure, regulation and role of 3 beta-hydroxysteroid dehydrogenase, 17 beta-hydroxysteroid dehydrogenase and aromatase enzymes in the formation of sex steroids in classical and peripheral intracrine tissues, , Baillieres Clin Endocrinol Metab, 1994, 10.1016/s0950-351x(05)80261-7
  • Synthesis and antiestrogenic activity of diaryl thioether derivatives, , J Med Chem, 1994, 10.1021/jm00034a009
  • The gene for hereditary breast-ovarian cancer, BRCA1, maps distal to EDH17B2 in chromosome region 17q12-q21, , Hum Mol Genet, 1994, 10.1093/hmg/3.9.1679
  • Widespread tissue distribution of steroid sulfatase, 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase (3 beta-HSD), 17 beta-HSD 5 alpha-reductase and aromatase activities in the rhesus monkey, , Mol Cell Endocrinol, 1994, 10.1016/0303-7207(94)90056-6
  • Androgen receptor-mediated stimulation of 17 beta-hydroxysteroid dehydrogenase activity by dihydrotestosterone and medroxyprogesterone acetate in ZR-75-1 human breast cancer cells, , Endocrinology, 1993, 10.1210/endo.132.1.8380373
  • Combination therapy for prostate cancer. Endocrine and biologic basis of its choice as new standard first-line therapy, , Cancer, 1993, 10.1002/1097-0142(19930201)71:3+<1059::aid-cncr2820711426>3.0.co;2-6
  • Detection of polymorphisms in the estradiol 17 beta-hydroxysteroid dehydrogenase II gene at the EDH17B2 locus on 17q11-q21, , Hum Mol Genet, 1993, 10.1093/hmg/2.4.479
  • Genetic mapping of the breast-ovarian cancer syndrome to a small interval on chromosome 17q12-21: exclusion of candidate genes EDH17B2 and RARA, , Hum Mol Genet, 1993, 10.1093/hmg/2.8.1193
  • Intracrinology: the basis for the rational design of endocrine therapy at all stages of prostate cancer, , Eur Urol, 1993, 10.1159/000474399
  • Molecular basis of congenital adrenal hyperplasia due to 3 beta-hydroxysteroid dehydrogenase deficiency, , Mol Endocrinol, 1993, 10.1210/mend.7.5.8316254
  • Science behind total androgen blockade: from gene to combination therapy, , Clin Invest Med, 1993
  • Structure and control of expression of the 3b-HSD and 17b-HSD genes in classical steroidogenic and peripheral intracrine tissues, , Molecular Basis of Reproductive Endocrinology, 1993
  • Structure and tissue-specific expression of a novel member of the rat 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase (3 beta-HSD) family. The exclusive 3 beta-HSD gene expression in the skin, , J Biol Chem, 1993
  • Structure-function relationships of multiple rat members of the 3b-hydroxysteroid dehydrogenase family (Chapter 14), , Molecular Basis of Reproductive Endocrinology, 1993
  • [Structure and expression of the genes encoding the enzymes for ovarian and peripheral steroidogenesis], , J Gynecol Obstet Biol Reprod (Paris), 1992
  • Additive stimulatory action of glucocorticoids and androgens on basal and estrogen-repressed apolipoprotein-D messenger ribonucleic acid levels and secretion in human breast cancer cells, , Endocrinology, 1992, 10.1210/endo.130.3.1537279
  • Androgenic 17 beta-hydroxysteroid dehydrogenase activity of expressed rat type I 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase, , Endocrinology, 1992, 10.1210/endo.130.1.1309351
  • Androgens and breast cancer, , Cancer Detect Prev, 1992
  • Assignment of the gene encoding the catalytic subunit C beta of cAMP-dependent protein kinase to the p36 band on chromosome 1, , Hum Genet, 1992, 10.1007/bf02265292
  • Cloning, expression and regulation of tissue-specific expression of 3b-hydroxysteroid dehydrogenase/D5-D4 isomerase, , Cellular and molecular biology of the adrenal cortex: proceedings of the 5th International Symposium on Cellular and Molecular Biology of the Adrenal Cortex held in Avignon (France) August 27-29, 1992, 1992
  • Congenital adrenal hyperplasia due to point mutations in the type II 3 beta-hydroxysteroid dehydrogenase gene, , Nat Genet, 1992, 10.1038/ng0792-239
  • Distribution of 17 beta-hydroxysteroid dehydrogenase gene expression and activity in rat and human tissues, , J Steroid Biochem Mol Biol, 1992, 10.1016/0960-0760(92)90390-5
  • Expression of liver-specific member of the 3 beta-hydroxysteroid dehydrogenase family, an isoform possessing an almost exclusive 3-ketosteroid reductase activity, , J Biol Chem, 1992
  • Localization of the catalytic subunit C gamma of the cAMP-dependent protein kinase gene (PRKACG) to human chromosome region 9q13, , Cytogenet Cell Genet, 1992, 10.1159/000133286
  • Localization of the human gene for the type I cyclic GMP-dependent protein kinase to chromosome 10, , Cytogenet Cell Genet, 1992, 10.1159/000133267
  • Mapping of the regulatory subunits RI beta and RII beta of cAMP-dependent protein kinase genes on human chromosome 7, , Genomics, 1992, 10.1016/s0888-7543(05)80284-8
  • Ontogeny and subcellular localization of 3 beta-hydroxysteroid dehydrogenase (3 beta-HSD) in the human and rat adrenal, ovary and testis, , J Steroid Biochem Mol Biol, 1992, 10.1016/0960-0760(92)90084-v
  • Ovarian 3 beta-hydroxysteroid dehydrogenase and sulfated glycoprotein-2 gene expression are differentially regulated by the induction of ovulation, pseudopregnancy, and luteolysis in the immature rat, , Endocrinology, 1992, 10.1210/endo.130.4.1547735
  • Regulation of 3-ketosteroid reductase messenger ribonucleic acid levels and 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4-isomerase activity in rat liver by sex steroids and pituitary hormones, , Endocrinology, 1992, 10.1210/endo.131.6.1446638
  • Structure and tissue-specific expression of 3 beta-hydroxysteroid dehydrogenase/5-ene-4-ene isomerase genes in human and rat classical and peripheral steroidogenic tissues, , J Steroid Biochem Mol Biol, 1992, 10.1016/0960-0760(92)90368-s
  • Structure function and tissue-specific gene expression of 3beta-hydroxysteroid dehydrogenase/5-ene-4-ene isomerase enzyme in classical and peripheral intracrine steroidogenic tissues, , J Steroid Biochem Mol Biol, 1992
  • Structure of human type II 5 alpha-reductase gene, , Endocrinology, 1992, 10.1210/endo.131.3.1505484
  • Variations of pre-proNPY mRNA in the arcuate nucleus during the rat estrous cycle, , Neuroreport, 1992, 10.1097/00001756-199203000-00009
  • Androgens in post-menopause, , Riv Ostet Ginecol Prat Med Perinat, 1991
  • Characteristics of the biphasic action of androgens and of the potent antiproliferative effects of the new pure antiestrogen EM-139 on cell cycle kinetic parameters in LNCaP human prostatic cancer cells, , Cancer Res, 1991
  • Characterization of macaque 3 beta-hydroxy-5-ene steroid dehydrogenase/delta 5-delta 4 isomerase: structure and expression in steroidogenic and peripheral tissues in primate, , Mol Cell Endocrinol, 1991, 10.1016/0303-7207(91)90224-g
  • Characterization of rat 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase cDNAs and differential tissue-specific expression of the corresponding mRNAs in steroidogenic and peripheral tissues, , J Biol Chem, 1991
  • Characterization of the structure-activity relationships of rat types I and II 3 beta-hydroxysteroid dehydrogenase/delta 5 -delta 4 isomerase by site-directed mutagenesis and expression in HeLa cells, , J Biol Chem, 1991
  • Codon 367 polymorphism of the human type I 3 beta-hydroxysteroid dehydrogenase/isomerase gene (HS5DB3), , Nucleic Acids Res, 1991, 10.1093/nar/19.21.6060
  • Detection of frequent BglII polymorphism by polymerase chain reaction and TaqI restriction fragment length polymorphism for 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase at the human HSD beta 3 locus (1p11-p13), , Hum Genet, 1991, 10.1007/bf00201743
  • Dopaminergic regulation of pre-proNPY mRNA levels in the rat arcuate nucleus, , Neurosci Lett, 1991, 10.1016/0304-3940(91)90903-7
  • Expression of 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase (3 beta-HSD) and 17 beta-hydroxysteroid dehydrogenase (17 beta-HSD) in adipose tissue, , Int J Obes, 1991
  • Inhibition of cell cycle kinetics and proliferation by the androgen 5 alpha-dihydrotestosterone and antiestrogen N,n-butyl-N-methyl-11-[16' alpha-chloro-3',17 beta-dihydroxy-estra-1',3',5'-(10')triene-7' alpha-yl] undecanamide in human breast cancer ZR-75-1 cells, , Cancer Res, 1991
  • Localization of endogenous benzodiazepine ligand octadecaneuropeptide (ODN) and peripheral benzodiazepine receptors in the rat prostate, , Molecular Andrology, 1991
  • Localization of peripheral benzodiazepine binding sites and diazepam-binding inhibitor (DBI) mRNA in mammary glands and dimethylbenz(a)antracene (DMBA)-induced mammary tumors in the rat, , Regul Pept, 1991, 10.1016/0167-0115(91)90229-a
  • Molecular cloning of rat 3b-hydroxysteroid dehydrogenase/D5-D4 isomerase: structure of two types of cDNAs and differential expression of the corresponding mRNAs in the ovary (Chapter 28), , Signaling Mechanisms and Gene Expression in the Ovary, 1991
  • Ontogenesis of 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase in the rat adrenal as revealed by immunocytochemistry and in situ hybridization, , Endocrinology, 1991, 10.1210/endo-129-5-2687
  • Stimulation of apolipoprotein D secretion by steroids coincides with inhibition of cell proliferation in human LNCaP prostate cancer cells, , Cancer Res, 1991
  • Structure and expression of a new complementary DNA encoding the almost exclusive 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4-isomerase in human adrenals and gonads, , Mol Endocrinol, 1991, 10.1210/mend-5-8-1147
  • Variations of pre-prosomatostatin mRNA levels in the hypothalamic periventricular nucleus during the rat estrous cycle, , Mol Cell Neurosci, 1991
  • A common ancestor for mammalian 3 beta-hydroxysteroid dehydrogenase and plant dihydroflavonol reductase, , Biochem J, 1990, 10.1042/bj2690558
  • Characterization of human 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4-isomerase gene and its expression in mammalian cells, , J Biol Chem, 1990
  • Glucocorticoid regulation of proopiomelanocortin mRNA levels in rat arcuate nucleus, , Mol Cell Neurosci, 1990
  • Influence of the duration of androgen deprivation on the sensitivity of the rat ventral prostate to dehydroepiandrosterone and androstenedione, , Ann N Y Acad Sci, 1990
  • Interactions between estrogens, androgens, progestins, and glucocorticoids in ZR-75-1 human breast cancer cells, , Ann N Y Acad Sci, 1990, 10.1111/j.1749-6632.1990.tb34288.x
  • Localization of 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4-isomerase in rat gonads and adrenal glands by immunocytochemistry and in situ hybridization, , Endocrinology, 1990, 10.1210/endo-127-3-1394
  • Localization of the endogenous benzodiazepine ligand octadecaneuropeptide in the rat testis, , Endocrinology, 1990, 10.1210/endo-127-4-1986
  • Multihormonal control of pre-pro-somatostatin mRNA levels in the periventricular nucleus of the male and female rat hypothalamus, , Neuroendocrinology, 1990, 10.1159/000125639
  • Opposite effects of estrogen and the progestin R5020 on cell proliferation and GCDFP-15 expression in ZR-75-1 human breast cancer cells, , Mol Cell Endocrinol, 1990, 10.1016/0303-7207(90)90130-z
  • Potent antagonism between estrogens and androgens on GCDFP-15 expression and cell growth in the ZR-75-1 human breast cancer cells, , Ann N Y Acad Sci, 1990, 10.1111/j.1749-6632.1990.tb17805.x
  • Pure antagonistic effect of a new steroidal antiestrogen in rat anterior pituitary cells in culture and in mouse uterus, , Ann N Y Acad Sci, 1990
  • Purification, cloning, complementary DNA structure, and predicted amino acid sequence of human estradiol 17 beta-dehydrogenase, , Ann N Y Acad Sci, 1990, 10.1111/j.1749-6632.1990.tb34281.x
  • Regulation of 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase expression and activity in the hypophysectomized rat ovary: interactions between the stimulatory effect of human chorionic gonadotropin and the luteolytic effect of prolactin, , Endocrinology, 1990, 10.1210/endo-127-6-2726
  • Regulation of progesterone-binding breast cyst protein GCDFP-24 secretion by estrogens and androgens in human breast cancer cells: a new marker of steroid action in breast cancer, , Endocrinology, 1990, 10.1210/endo-126-6-3223
  • Structure and sexual dimorphic expression of a liver-specific rat 3 beta-hydroxysteroid dehydrogenase/isomerase, , Endocrinology, 1990, 10.1210/endo-127-6-3237
  • Structure of two in tandem human 17 beta-hydroxysteroid dehydrogenase genes, , Mol Endocrinol, 1990, 10.1210/mend-4-2-268
  • Synthèse périphérique des androgènes chez l'homme. Génétique moléculaire du système et sa prise en compte dans le traitement du cancer de la prostate, , Med Sci (Paris), 1990
  • Synthetic progestins stimulate prostatic binding protein messenger RNAs in the rat ventral prostate, , Mol Cell Endocrinol, 1990, 10.1016/0303-7207(90)90190-j
  • Antagonism between estrogens and androgens on GCDFP-15 gene expression in ZR-75-1 cells and correlation between GCDFP-15 and estrogen as well as progesterone receptor expression in human breast cancer, , J Steroid Biochem, 1989, 10.1016/0022-4731(89)90115-5
  • Characterization of cDNAs for human estradiol 17 beta-dehydrogenase and assignment of the gene to chromosome 17: evidence of two mRNA species with distinct 5'-termini in human placenta, , Mol Endocrinol, 1989, 10.1210/mend-3-8-1301
  • Characterization of two mRNA species encoding human estradiol 17 beta-dehydrogenase and assignment of the gene to chromosome 17, , J Steroid Biochem, 1989, 10.1016/0022-4731(89)90082-4
  • Conversion of precursor adrenal steroids into potent androgens in peripheral tissue, , Early stage prostate cancer: diagnosis and choice of treatment: proceedings of the International Symposium on Diagnosis and Treatment of Early Stage Prostate Cancer, held in Quebec City, Canada, on 3 October 1988, 1989
  • Down-regulation of estrogen receptors by androgens in the ZR-75-1 human breast cancer cell line, , Endocrinology, 1989, 10.1210/endo-125-1-392
  • Electron microscopic autoradiographic localization of prolactin mRNA in rat pituitary, , J Histochem Cytochem, 1989, 10.1177/37.5.2703695
  • Inhibitory effect of androgen on estrogen-induced prolactin messenger ribonucleic acid accumulation in the male rat anterior pituitary gland, , Endocrinology, 1989, 10.1210/endo-125-4-1821
  • Inhibitory effect of estrogens on GCDFP-15 mRNA levels and secretion in ZR-75-1 human breast cancer cells, , Mol Endocrinol, 1989, 10.1210/mend-3-4-694
  • Localization of peptide gene expression by in situ hybridization at the electron microscopic level, , Gene probes, 1989
  • Molecular cloning, cDNA structure and predicted amino acid sequence of bovine 3 beta-hydroxy-5-ene steroid dehydrogenase/delta 5-delta 4 isomerase, , FEBS Lett, 1989, 10.1016/0014-5793(89)81516-9
  • Regulation of pro-gonadotropin-releasing hormone gene expression by sex steroids in the brain of male and female rats, , Mol Endocrinol, 1989, 10.1210/mend-3-11-1748
  • Stimulation of androgen-dependent gene expression by the adrenal precursors dehydroepiandrosterone and androstenedione in the rat ventral prostate, , Endocrinology, 1989, 10.1210/endo-124-6-2745
  • Androgènes, , Pharmacologie clinique: bases de la thérapeutique, 1988
  • Cloning of the human androgen receptor cDNA, , Hormones and cancer 3: proceedings of the Third International Congress on Hormones and Cancer, 1988
  • Combination therapy with the antiandrogen Flutamide and the LHRH agonist [D-Trp6, des-Gly-NH210]LHRH ethylamide in prostate cancer: rationale and 5-year clinical experience, , Molecular biology of brain and endocrine peptidergic systems, 1988
  • Effect of luteinizing hormone releasing hormone (LHRH) and [D-Trp6, des-Gly-NH2(10)]LHRH ethylamide on alpha-subunit and LH beta messenger ribonucleic acid levels in rat anterior pituitary cells in culture, , Mol Endocrinol, 1988, 10.1210/mend-2-6-521
  • Effects of sex steroids on regulation of the levels of C1 peptide of rat prostatic steroid-binding protein mRNA evaluated by in-situ hybridization, , J Mol Endocrinol, 1988, 10.1677/jme.0.0010213
  • Full oestrogenic activity of C19-delta 5 adrenal steroids in rat pituitary lactotrophs and somatotrophs, , Mol Cell Endocrinol, 1988, 10.1016/0303-7207(88)90138-4
  • Isolation and sequence of the human glucocorticoid receptor gene promoter, , Steroid receptors in health and disease, 1988
  • Modulation by sex steroids and [D-Trp6, Des-Gly-NH2(10)]luteinizing hormone (LH)-releasing hormone ethylamide of alpha-subunit and LH beta messenger ribonucleic acid levels in the rat anterior pituitary gland, , Mol Endocrinol, 1988, 10.1210/mend-2-9-775
  • Adrenal C19-5-ene steroids induce full estrogenic responses in rat pituitary gonadotrophs, , J Steroid Biochem, 1987, 10.1016/0022-4731(87)90005-7
  • Adrenal steroids exert potent estrogen action in both normal and cancer tissue, , Hormonal manipulation of cancer: peptides, growth factors, and new (anti)steroidal agents, 1987
  • Combination therapy in stage C and D prostatic cancer: rationale and five year clinical experience, , Cancer Metastasis Rev, 1987, 10.1007/bf00047470
  • Flutamide in combination with castration (surgical or medical) is the standard treatment in advanced prostate cancer, , Journal of drug development, 1987
  • Multiple factors controlling ACTH secretion at the anterior pituitary level, , Ann N Y Acad Sci, 1987, 10.1111/j.1749-6632.1987.tb24953.x
  • New concepts on the androgen sensitivity of prostate cancer, , Prog Clin Biol Res, 1987
  • Somatostatin prevents the desensitizing action of growth hormone-releasing factor on growth hormone release, , Peptides, 1987, 10.1016/0196-9781(87)90090-8
  • Atrial natriuretic factor does not affect basal, forskolin- and CRF-stimulated adenylate cyclase activity, cAMP formation or ACTH secretion, but does stimulate cGMP synthesis in anterior pituitary, , Mol Cell Endocrinol, 1986, 10.1016/0303-7207(86)90054-7
  • Atrial natriuretic factor-induced cGMP accumulation in rat anterior pituitary cells in culture is not coupled to hormonal secretion, , Regul Pept, 1986, 10.1016/0167-0115(86)90068-6
  • Characteristics of interaction of the antiandrogen flutamide with the androgen receptor in various target tissues, , Mol Cell Endocrinol, 1986, 10.1016/0303-7207(86)90132-2
  • Characteristics of the desensitization of growth hormone and cyclic AMP responses to growth hormone-releasing factor and prostaglandin E2 in rat anterior pituitary cells in culture, , Mol Cell Endocrinol, 1986, 10.1016/0303-7207(86)90072-9
  • Regulation of growth hormone mRNA and pro-opiomelanocortin mRNA levels by cyclic AMP in rat anterior pituitary cells in culture, , DNA, 1986, 10.1089/dna.1986.5.263
  • Stimulation of growth hormone release and synthesis by estrogens in rat anterior pituitary cells in culture, , Endocrinology, 1986, 10.1210/endo-119-5-2004
  • Keoxifene shows pure antiestrogenic activity in pituitary gonadotrophs, , Mol Cell Endocrinol, 1985, 10.1016/0303-7207(85)90131-5
  • Steroid modulation of LHRH action, , Steroid modulation of neuroendocrine function; Sterols, steroids, and bone metabolism: proceedings of the XI Meeting of the International Study Group for Steroid Hormones, Rome, November 30-December 2, 1983, 1984
  • Enhanced urinary prostaglandin E2 in postobstructive diuresis in humans, , Prostaglandins Med, 1980, 10.1016/0161-4630(80)90087-7

Contribution à l'enseignement aux cycles supérieurs

Étudiant(e)s dirigé(e)s*

Depuis 2009
  • Jolyane Blouin-Bougie - Doctorat - En cours
  • Anne-Laure Renault - Maitrîse avec mémoire - 2014/01
  • Martin Leclerc - Doctorat - 2016/01
  • Mandy Ducy - Maitrîse avec mémoire - 2018/09

Encadrement d'étudiant(e)s pour les programmes suivants :

Disponibilité d'encadrement d'étudiant(e)s

Ce (cette) professeur(e) est présentement à la recherche d'étudiant(e)s.

Envoyer un courriel
*Les supervisions d’étudiant(e)s de 1er cycle en stage de recherche et de résident(e)s aux études médicales postdoctorales seront répertoriées ultérieurement.

Direction et personnes-ressources

Vice-décanat à la recherche et aux études supérieures
Pavillon Ferdinand-Vandry
Université Laval
1050, avenue de la Médecine,  local 4645
Québec, Québec G1V 0A6
Canada

Renseignements - Secrétariat :
vdres@fmed.ulaval.ca
Téléphone 418 656-2690

Jacques Simard
Vice-doyen à la recherche et aux études supérieures
vice-doyen.recherche-et-etudes-superieures@fmed.ulaval.ca

Louise Laperrière
Adjointe au vice-doyen à la recherche et aux études supérieures
louise.laperriere@fmed.ulaval.ca 

Volet recherche
Gestion financière
Volet études aux cycles supérieurs